Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) saw unusually-high trading volume on Friday . Approximately 594,300 shares traded hands during trading, an increase of 5% from the previous session’s volume of 563,967 shares.The stock last traded at $14.75 and had previously closed at $14.15.

MNTA has been the topic of a number of recent research reports. Zacks Investment Research downgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, December 4th. Stifel Nicolaus reaffirmed a “hold” rating and set a $15.00 price target (down previously from $22.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday, October 4th. Barclays reaffirmed an “equal weight” rating and set a $16.00 price target (down previously from $17.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday, October 4th. BidaskClub downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and set a $14.00 price target (down previously from $18.00) on shares of Momenta Pharmaceuticals in a research note on Thursday, October 5th. Two equities research analysts have rated the stock with a sell rating and ten have given a hold rating to the company’s stock. Momenta Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $15.00.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.03. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The company had revenue of $24.09 million for the quarter, compared to analysts’ expectations of $29.58 million. During the same period in the prior year, the business earned ($0.26) EPS. The firm’s quarterly revenue was down 17.3% on a year-over-year basis. sell-side analysts anticipate that Momenta Pharmaceuticals, Inc. will post -1.16 earnings per share for the current fiscal year.

In other Momenta Pharmaceuticals news, CEO Craig A. Wheeler sold 4,116 shares of the stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $13.35, for a total transaction of $54,948.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Elizabeth Stoner sold 5,500 shares of the stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $13.10, for a total transaction of $72,050.00. Following the sale, the director now directly owns 13,240 shares of the company’s stock, valued at $173,444. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 49,505 shares of company stock worth $685,923. 4.40% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in the stock. FMR LLC raised its position in shares of Momenta Pharmaceuticals by 3.3% in the 2nd quarter. FMR LLC now owns 11,125,193 shares of the biotechnology company’s stock valued at $188,015,000 after purchasing an additional 351,743 shares during the last quarter. BlackRock Inc. raised its position in Momenta Pharmaceuticals by 7.1% during the 2nd quarter. BlackRock Inc. now owns 9,400,485 shares of the biotechnology company’s stock worth $158,868,000 after buying an additional 626,415 shares during the last quarter. Vanguard Group Inc. raised its position in Momenta Pharmaceuticals by 4.9% during the 2nd quarter. Vanguard Group Inc. now owns 6,243,767 shares of the biotechnology company’s stock worth $105,519,000 after buying an additional 290,090 shares during the last quarter. State Street Corp raised its position in Momenta Pharmaceuticals by 8.1% during the 2nd quarter. State Street Corp now owns 2,653,427 shares of the biotechnology company’s stock worth $44,842,000 after buying an additional 197,978 shares during the last quarter. Finally, Palo Alto Investors LLC raised its position in Momenta Pharmaceuticals by 1.6% during the 2nd quarter. Palo Alto Investors LLC now owns 1,787,576 shares of the biotechnology company’s stock worth $30,210,000 after buying an additional 28,200 shares during the last quarter. 93.40% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Momenta Pharmaceuticals (MNTA) Sees Large Volume Increase” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/01/07/momenta-pharmaceuticals-mnta-sees-large-volume-increase.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.